Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 14Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2

Interventions

Radiotherapy, Conformal 2Radiotherapy 2Paclitaxel 2Nivolumab 2Carboplatin 2veliparib 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1Taxes 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Platinum 1Metformin 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Docetaxel 1Disulfides 1Cisplatin 1CTLA-4 Antigen 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Bronchiolo-Alveolar × Disulfides × 90 days × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡